CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis

Recruiting now · Not applicable

Conditions studied: Severe Aortic Stenosis

In brief

Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia. This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.

Key facts

Study ID

NCT07469371

Run by

Yan'an Affiliated Hospital of Kunming Medical University

People needed

300

Starts

2026-04-01

Expected to finish

2027-12-01

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years.
• Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m/s, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² [or indexed aortic valve area (AVAi) ≤0.6 cm²/m²].
• New York Heart Association (NYHA) functional class II or higher.
• Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).
• Undergoing preoperative coronary computed tomography angiography (CCTA).
• Willing to participate in the study and able to provide written informed consent.

You may not qualify if…

• Allergy to prosthetic valve materials or iodinated contrast agents.
• Contraindication or allergic reaction to anticoagulants or antiplatelet agents, or inability to tolerate required anticoagulant or antiplatelet therapy.
• Active infective endocarditis or any other active infection.
• Severe vascular disease precluding safe implantation of a prosthetic valve.
• Ascending aortic diameter ≥50 mm.
• Prior prosthetic valve implantation in any cardiac position or prior coronary artery bypass grafting (CABG).
• Preoperative imaging confirming aortic root anatomy unsuitable for transcatheter aortic valve implantation.
• Intracardiac mass, left ventricular or left atrial thrombus, or vegetation confirmed by preoperative echocardiography.
• Acute myocardial infarction within 30 days before surgery.
• Clinically diagnosed stroke or transient ischemic attack within 3 months before surgery.
• Bleeding or coagulation disorders within 3 months before surgery that required hospitalization or blood transfusion or were otherwise clinically significant and would preclude the antiplatelet therapy required in this study.

Where it is running

• Yan'an Hospital Affiliated to Kunming Medical University — Kunming, Yunnan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.